Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15964831 | 0.84 | CYP11B1 (0.34) | CYP11B1CYP11B2NNMTCYP17A1CYP1A2 | |
| SCHEMBL3706200 | 0.76 | CYP11B1 (0.35) | CYP11B1CYP11B2NNMTCYP17A1CYP1A2 | |
| SCHEMBL31125012 | 0.75 | CYP11B2 (0.38) | CYP11B1CYP11B2CYP17A1CYP1A2CYP19A1 | |
| SCHEMBL2396438 | 0.74 | PIN1 (0.31) | — | |
| SCHEMBL3542184 | 0.72 | SMN1; SMN2 (0.40) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL29673365 | 0.71 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL15964846 | 0.71 | CYP11B2 (0.34) | CYP11B1CYP11B2NNMTCYP17A1CYP1A2 | |
| SCHEMBL21663004 | 0.70 | SMN1; SMN2 (0.34) | CYP11B1CYP11B2TYRO3DYRK1BSMN1; SMN2 | |
| SCHEMBL21491524 | 0.69 | TYRO3 (0.32) | TYRO3DYRK1B | |
| SCHEMBL21492114 | 0.69 | SMN1; SMN2 (0.32) | TYRO3DYRK1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | CYP11B1 2/4885CYP11B2 1/4885NNMT 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.